MBC Alumni, Proteologix, Acquired by J&J for 850M

We are thrilled to announce that alumni company Proteologix Inc. has been acquired by Johnson & Johnson. This acquisition highlights Proteologix’s groundbreaking work in the treatment of atopic dermatitis.

Read original article

With four lab benches, Proteologix began their journey at MBC BioLabs in 2021 to develop their innovative therapies. Their rapid progress and commitment allowed them to “graduate” from our space in 2022, moving on to further their research and development in their own space.

The acquisition by Johnson & Johnson is a testament to the groundbreaking work Proteologix has accomplished. With this strategic move, Johnson & Johnson aims to lead the charge in treating atopic dermatitis, leveraging Proteologix’s cutting-edge technology and expertise. This partnership is set to accelerate the development of new therapies, bringing hope to millions of patients worldwide.

At MBC BioLabs, we believe that startups are the greatest for positive change in the world. We are dedicated to “enabling awesome” by fostering innovation and helping biotech companies achieve their goals. Proteologix’s journey from our labs to becoming a key player in the industry exemplifies the potential that lies within our wonderful community.

Proteologix’s success story is a powerful reminder of what can be achieved through innovation and dedication. We would like to congratulate the Proteologix team on this monumental achievement and look forward to their continued success in the years to come.